Genomatica and TeselaGen have signed a multi-year agreement to license TeselaGen’s software, which uses synthetic biology approaches to build and modify DNA. The two companies also will work together to enhance TeselaGen’s software to meet Genomatica’s objectives.
By using TeselaGen’s technology, Genomatica expects to accelerate development of its proprietary organisms. These organisms are an important part of the overall process technology that Genomatica delivers to its licensees for the production of major chemicals from renewable feedstocks. TeselaGen’s software provides an advanced biological computer aided design and manufacture system, with automated DNA design and assembly protocol generation.
“Genomatica’s deep expertise in microbial strain development is very valuable to TeselaGen as we develop our software to solve real problems faced by industrial biologists,” said Michael Fero, CEO, TeselaGen. “Our academic roots have given us a firm platform on which to build, but now we’re focused on meeting the needs of industrial customers working to solve very difficult practical problems. This new relationship with Genomatica is ideal from our perspective.”
“TeselaGen’s experience and capabilities in automated DNA design and cloning will be very helpful to Genomatica as we continue to advance high-throughput technologies for strain engineering,” said Mark Burk, CTO, Genomatica. “We have seen many different technologies emerging in this space, and TeselaGen brought clear, distinct and compelling value.”